Gilead Goes Full Steam Ahead In Oncology With Big Lung Cancer Push

Islatravir/Lenacapavir Program Under Way Again

 
• By Alaric DeArment
  
In its third quarter earnings, Gilead highlighted its drug development efforts in oncology, infectious and inflammatory diseases • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business